This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (37)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Hagob Kantarjian, MD; Hwee-Yong Yap, MD; Gabriel Hortobagyi, MD; Aman Buzdar, MD; George Blumenschein, MD

Arch Intern Med. 1983;143(2):237-240.

Abstract
• Forty-one men with metastatic breast cancer were treated with 70 trials of hormone therapy. These included 25 orchiectomies and 45 additive hormonal treatments. The overall response rate was 31%. The response rate was 32% to orchiectomy, 17% to estrogens, 43% to steroids, 25% to tamoxifen citrate, and 60% to androgens. The response to additive hormonal therapy was 31% and was not affected by prior orchiectomy (33% v 30%). Median overall response duration was 12 months, 17.5 months following orchiectomy, 8.5 months following additive hormonal therapy, five months following estrogens, 11 months following steroids, and eight months following androgens. Median survival from first metastasis was significantly prolonged in patients responding to orchiectomy and additive hormonal therapy. Patients with a disease-free interval (DFI) longer than 12 months had a 59% response rate to hormonal therapy compared with 9% of those with a DFI no more than 12 months. Response to one form of hormonal therapy did not predict later hormonal response. Ablative and additive hormonal therapy offer effective palliation to one third of male breast cancer patients, produce little toxic effects and morbidity, and improve survival duration after metastasis in responders.

(Arch Intern Med 1983;143:237-240)

Author Affiliations
From the Department of Developmental Therapeutics (Dr Kantarjian) and Medical Breast Service, Department of Internal Medicine (Drs Yap, Hortobagyi, Buzdar, and Blumenschein), The University of Texas, M. D. Anderson Hospital and Tumor Institute at Houston.

Footnotes
Accepted for publication Oct 18, 1982.

Reprint requests to Developmental Therapeutics, M. D. Anderson Hospital and Tumor Institute, 6723 Bertner Ave, Houston, TX 77030 (Dr Kantarjian).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Some Aspects of the Endocrine Profile and Management of Hormone-Dependent Male Breast Cancer
Dimitrov et al.
The Oncologist 2007;12:798-807.
ABSTRACT | FULL TEXT  

Breast Cancer in Men
Giordano et al.
ANN INTERN MED 2002;137:678-687.
ABSTRACT | FULL TEXT  

Carcinoma of the Male Breast
Jaiyesimi et al.
ANN INTERN MED 1992;117:771-777.
ABSTRACT  

Ketoconazole for Male Metastatic Breast Cancer
FELDMAN
ANN INTERN MED 1986;104:123-124.
ABSTRACT